Baxdrostat was effective in lowering systolic blood pressure, but increased the risk of hyperkalemia, which supports it as an alternative therapy for uncontrolled and resistant hypertension, with cautious use in patients at risk for hyperkalemia.
Abstract
Aldosterone synthase inhibitors (ASI) have recently emerged as alternative options for the treatment of uncontrolled and resistant hypertension. Baxdrostat, a highly selective ASI, has been studied in different trials, yielding mixed results. This meta-analysis aimed to summarize its effects on blood pressure and risk of hyperkalemia.
A systematic search was conducted on PubMed, Embase, Cochrane and unpublished data for randomized controlled trials (RCT) comparing baxdrostat to placebo for the treatment of patients with uncontrolled and resistant hypertension. The main efficacy outcome was reduction in systolic blood pressure (SBP) and the main safety outcome was the incidence of hyperkalemia. Baxdrostat arms were pooled for trials evaluating multiple doses. Pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) were estimated using a random-effects model with the Restricted Maximum Likelihood estimator.
Five RCTs with 1729 total patients were included. Baxdrostat significantly reduced SBP (MD -7.08 mmHg; 95% CI -11.68, -2.47; p = 0.01; I² = 73%) and DBP (MD -3.01 mmHg; 95% CI -5.7, -0.31; p = 0.04; I² = 64%) compared to placebo. There was, however, a significant increase in the incidence of hyperkalemia (RR 5.35; 95% CI 1.76, 16.25; NNH 19; I² = 0) and change in serum potassium (MD 0.4 mmol/L; 95% CI 0.26, 0.54).
Baxdrostat was effective in lowering systolic blood pressure, but increased the risk of hyperkalemia. These results support it as an alternative therapy for uncontrolled and resistant hypertension, with cautious use in patients at risk for hyperkalemia. New evidence is needed for long-term cardiovascular and renal outcomes, as well as comparisons with mineralocorticoid receptor antagonists and other ASIs, concerning efficacy and safety.
SBP forest plot HyperK forest plot
Findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonis...
Muhammad Burhan, Z. Shahid, M. Naveed et al.· The Annals of Pharmacotherap...· 0 citations
Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.
Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al.· European Journal of Clinical...· 2 citations
Treatment selection should prioritize treatments with demonstrated superiority over baseline treatment, including spironolactone, baxdrostat, and radiofrequency renal denervation in patients with resistant or uncontrolled hypertension.
Angelo Laino, R. Piccolo, A. Vitale et al.· JACC: Advances· 0 citations
Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...
G. Marino, S. D. Di Fusco, E. Graziano et al.· Journal of Clinical Medicine· 0 citations
Hypertension remains the leading modifiable risk factor for cardiovascular disease, yet control rates are suboptimal due to poor adherence and blood pressure (BP) variability with daily oral regimens. Zilebesiran is an investigational RNA interference therapeutic targeting hepatic angiotensinogen (AGT) synthesis....
T. Bonafé, G. A. Alves, B. M. Gomes et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.